Volume 9, Issue 6, Pages (June 2004)

Slides:



Advertisements
Similar presentations
Molecular Therapy - Oncolytics
Advertisements

Volume 14, Issue 3, Pages (September 2006)
Molecular Therapy - Oncolytics
Jennifer R. Hamilton, Gayathri Vijayakumar, Peter Palese  Cell Reports 
Brian Hutzen, Chun-Yu Chen, Pin-Yi Wang, Les Sprague, Hayley M
Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy  Che-Hsin Lee, Chao-Liang Wu, Yun-Sheng.
Volume 7, Issue 3, Pages (March 2003)
Molecular Therapy - Oncolytics
Volume 10, Issue 5, Pages (November 2004)
Volume 9, Issue 6, Pages (June 2004)
Pre-existing Immunity and Passive Immunity to Adenovirus 5 Prevents Toxicity Caused by an Oncolytic Adenovirus Vector in the Syrian Hamster Model  Debanjan.
Volume 9, Issue 4, Pages (April 2004)
Human Papilloma Virus E6 and E7 Proteins Support DNA Replication of Adenoviruses Deleted for the E1A and E1B Genes  Dirk S. Steinwaerder, Cheryl A. Carlson,
Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer 
Volume 10, Issue 6, Pages (December 2004)
Volume 20, Issue 12, Pages (December 2012)
Volume 18, Issue 11, Pages (November 2010)
Volume 7, Issue 2, Pages (February 2003)
Volume 9, Issue 6, Pages (June 2004)
Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy
Volume 15, Issue 5, Pages (May 2007)
Volume 18, Issue 9, Pages (September 2010)
Volume 3, Issue 2, Pages (February 2001)
Volume 22, Issue 1, Pages (January 2014)
Incorporation of the B18R Gene of Vaccinia Virus Into an Oncolytic Herpes Simplex Virus Improves Antitumor Activity  Xinping Fu, Armando Rivera, Lihua.
Volume 8, Issue 3, Pages (September 2003)
Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models  Fabrice Le Boeuf, Simon Gebremeskel,
In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis
Volume 2, Issue 4, Pages (October 2000)
Volume 23, Issue 4, Pages (April 2015)
Volume 23, Issue 4, Pages (April 2015)
Volume 13, Issue 1, Pages (January 2006)
Volume 12, Issue 5, Pages (November 2005)
Hannah Chen, Padma Sampath, Weizhou Hou, Stephen H. Thorne 
Volume 19, Issue 10, Pages (October 2011)
Volume 16, Issue 6, Pages (June 2008)
Thomas S. Griffith, Elizabeth L. Broghammer  Molecular Therapy 
Volume 17, Issue 2, Pages (February 2009)
Volume 10, Issue 4, Pages (October 2004)
Volume 22, Issue 1, Pages (January 2014)
Volume 13, Issue 5, Pages (May 2006)
Volume 20, Issue 5, Pages (May 2012)
Volume 24, Issue 1, Pages (January 2016)
Elizabeth M Hadac, Elizabeth J Kelly, Stephen J Russell 
Sangeet Lal, Corey Raffel  Molecular Therapy - Oncolytics 
Volume 18, Issue 5, Pages (May 2010)
Volume 6, Issue 3, Pages (September 2002)
Volume 18, Issue 8, Pages (August 2010)
Molecular Therapy - Oncolytics
Volume 26, Issue 1, Pages (January 2018)
Valerie Künzi, Patrick A
Volume 10, Issue 6, Pages (December 2004)
Volume 25, Issue 4, Pages (April 2017)
Volume 6, Issue 5, Pages (November 2002)
Volume 23, Issue 3, Pages (March 2015)
Therapeutic Efficacy of G207, a Conditionally Replicating Herpes Simplex Virus Type 1 Mutant, for Gallbladder Carcinoma in Immunocompetent Hamsters  Kenji.
Volume 26, Issue 4, Pages (April 2018)
Volume 20, Issue 4, Pages (April 2012)
Volume 22, Issue 7, Pages (July 2014)
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism  Johann Foloppe, Juliette.
In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s
Volume 16, Issue 10, Pages (October 2008)
Volume 20, Issue 6, Pages (June 2012)
Volume 20, Issue 4, Pages (April 2012)
Volume 18, Issue 2, Pages (February 2010)
Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy  Adrian Pelin, Johann Foloppe, Julia Petryk, Ragunath.
Volume 18, Issue 10, Pages (October 2010)
Volume 15, Issue 2, Pages (February 2007)
Volume 12, Issue 5, Pages (November 2005)
Volume 15, Issue 6, Pages (June 2007)
Presentation transcript:

Volume 9, Issue 6, Pages 786-803 (June 2004) An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor- enhanced cancer selectivity and enhanced oncolytic potency  Ta-Chiang Liu, Gunnel Hallden, Yaohe Wang, Gabriel Brooks, Jennelle Francis, Nick Lemoine, David Kirn  Molecular Therapy  Volume 9, Issue 6, Pages 786-803 (June 2004) DOI: 10.1016/j.ymthe.2004.03.017 Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 1 Total viral replication in tumor cells is increased by E1B-19 kDa gene deletion. Cells were infected with 100 or 1000 ppc and harvested at indicated time points. Replication was assessed in the human tumor cells (A) PT45, (B) A2780, (C) A2780/CP, and (D) Hep3B; in murine tumor cells (E) CMT-167, (F) CMT-64, and (G) JC; and in human normal cells (H) NHBE. The resulting quantity of infectious virus was determined as described and values were normalized on an infectious unit produced per cell basis. Representative data from one experiment are shown here. Open bars, data from 48 h p.i.; black bars, data from 72 h p.i.; gray bars, data from 96 h p.i.; *level too low to be shown on the graph. Error bars represent standard errors between triplicates in one experiment. Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 2 Virus release is increased by E1B-19 kDa gene deletion. Cells were infected as described, and culture media were collected and titered at indicated time points. Virus release was assessed in the human tumor cells (A) PT45, (B) A2780, and (C) A2780/CP; in murine tumor cells (D) CMT-167, (E) CMT-64, and (F) JC; and in human normal cells (G) NHBE. The resulting quantity of infectious virus was determined as described and values were normalized on an infectious unit produced per cell basis. Representative data from one experiment are shown here. Open bars, data from 48 h p.i.; black bars, data from 72 h p.i.; gray bars, data from 96 h p.i.; *level too low to be shown on the graph. Error bars represent standard errors between triplicates in one experiment. Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 3 EC50 value comparison between dl250 and Ad2wt; potency is increased by E1B-19 kDa gene deletion. The dose–response curves of Ad2wt, dl250, and inactivated dl312 in different cell lines were obtained by MTS assay as described. The EC50 values of each virus were then determined and compared in human cancer cells (A) PT45, (B) A2780, (C) A2780CP, and (D) Hep3B; in murine cancer cells (E) CMT-167, (F) CMT-64, and (G) JC; and in normal human cells (H) NHBE. Representative data from one experiment are shown here. Red curves, dl250; green curves, Ad2wt; blue curves, PUV-inactivated dl312. Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 4 Effects of TNF-α on viral replication, cytopathic potency, and apoptosis induction. Viral replication, release, EC50, and apoptosis induction were measured with and without TNF treatment as described under Materials and Methods. Total viral replication was assessed in (A) PT45 cancer cells and (B) NHBE normal cells at 48, 72, and 96 h p.i., with/without TNF treatment. Viral release was assessed in (C) PT45 cancer cells and (D) NHBE normal cells at 48, 72, and 96 h p.i., with/without TNF treatment. Representative data from one experiment are shown here. Open bars, data from 48 h p.i.; black bars, data from 72 h p.i.; gray bars, data from 96 h p.i.; *TNF-α treatment; +level too low to be shown on the graph. Error bars represent standard errors between triplicates in one experiment. The percentage change in EC50 values of (E) Ad2wt and (F) dl250 after TNF treatment was studied. Error bars represent standard errors between different experiments (n = 4). In situ caspase-3 activation was determined in (G) NHBE and (H) PT45 cells as an indication of apoptosis induction. Cells were untreated or treated with viruses and/or TNF-α as described. At 24, 48, and 96 h p.i., cells were fixed and stained for active form caspase-3 as mentioned (n = 4). Open bars, data from 48 h p.i.; filled bars, data from 72 h p.i.; gray bars, data from 96 h p.i. Error bars represent standard errors between different experiments. Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 4 Effects of TNF-α on viral replication, cytopathic potency, and apoptosis induction. Viral replication, release, EC50, and apoptosis induction were measured with and without TNF treatment as described under Materials and Methods. Total viral replication was assessed in (A) PT45 cancer cells and (B) NHBE normal cells at 48, 72, and 96 h p.i., with/without TNF treatment. Viral release was assessed in (C) PT45 cancer cells and (D) NHBE normal cells at 48, 72, and 96 h p.i., with/without TNF treatment. Representative data from one experiment are shown here. Open bars, data from 48 h p.i.; black bars, data from 72 h p.i.; gray bars, data from 96 h p.i.; *TNF-α treatment; +level too low to be shown on the graph. Error bars represent standard errors between triplicates in one experiment. The percentage change in EC50 values of (E) Ad2wt and (F) dl250 after TNF treatment was studied. Error bars represent standard errors between different experiments (n = 4). In situ caspase-3 activation was determined in (G) NHBE and (H) PT45 cells as an indication of apoptosis induction. Cells were untreated or treated with viruses and/or TNF-α as described. At 24, 48, and 96 h p.i., cells were fixed and stained for active form caspase-3 as mentioned (n = 4). Open bars, data from 48 h p.i.; filled bars, data from 72 h p.i.; gray bars, data from 96 h p.i. Error bars represent standard errors between different experiments. Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 5 Adenovirus gene expression, replication, and infection-induced pathologic changes in normal liver tissue in vivo are inhibited by E1B-19 kDa deletion. Viruses were injected intravenously as described to infect the livers of immunocompetent mice. Viral gene expression, replication, pathology, and apoptosis induction by each virus were compared. (A) E1A expression (early viral gene). Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (B) Representative examples of E1A staining from each treatment group (original magnification 10 × 20). (C) PFU (plaque-forming unit) recovery. Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (D) Cytopathic effect severity (scoring as under Materials and Methods). Open bars, 24 h postinjection; black bars, 48 h postinjection; gray bars, 120 h p.i. Error bars represent standard errors between different animals. *Undetectable. (E) Periportal inflammation severity (scoring as under Materials and Methods). Open bar, 24 h postinjection; filled bar, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (F) Representative examples of histopathology from each treatment group (original magnification 10 × 20). Filled arrows, classical cytopathic effect in livers after viral infection—eosinophilic cytoplasm and intranuclear inclusion body; open arrow, lymphocytic infiltration; N, necrotic area. (G) Active caspase-3 levels (scoring as under Materials and Methods). Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (H) Representative examples of caspase-3 staining from each treatment group (original magnification 10 × 20). Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 5 Adenovirus gene expression, replication, and infection-induced pathologic changes in normal liver tissue in vivo are inhibited by E1B-19 kDa deletion. Viruses were injected intravenously as described to infect the livers of immunocompetent mice. Viral gene expression, replication, pathology, and apoptosis induction by each virus were compared. (A) E1A expression (early viral gene). Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (B) Representative examples of E1A staining from each treatment group (original magnification 10 × 20). (C) PFU (plaque-forming unit) recovery. Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (D) Cytopathic effect severity (scoring as under Materials and Methods). Open bars, 24 h postinjection; black bars, 48 h postinjection; gray bars, 120 h p.i. Error bars represent standard errors between different animals. *Undetectable. (E) Periportal inflammation severity (scoring as under Materials and Methods). Open bar, 24 h postinjection; filled bar, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (F) Representative examples of histopathology from each treatment group (original magnification 10 × 20). Filled arrows, classical cytopathic effect in livers after viral infection—eosinophilic cytoplasm and intranuclear inclusion body; open arrow, lymphocytic infiltration; N, necrotic area. (G) Active caspase-3 levels (scoring as under Materials and Methods). Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (H) Representative examples of caspase-3 staining from each treatment group (original magnification 10 × 20). Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 5 Adenovirus gene expression, replication, and infection-induced pathologic changes in normal liver tissue in vivo are inhibited by E1B-19 kDa deletion. Viruses were injected intravenously as described to infect the livers of immunocompetent mice. Viral gene expression, replication, pathology, and apoptosis induction by each virus were compared. (A) E1A expression (early viral gene). Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (B) Representative examples of E1A staining from each treatment group (original magnification 10 × 20). (C) PFU (plaque-forming unit) recovery. Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (D) Cytopathic effect severity (scoring as under Materials and Methods). Open bars, 24 h postinjection; black bars, 48 h postinjection; gray bars, 120 h p.i. Error bars represent standard errors between different animals. *Undetectable. (E) Periportal inflammation severity (scoring as under Materials and Methods). Open bar, 24 h postinjection; filled bar, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (F) Representative examples of histopathology from each treatment group (original magnification 10 × 20). Filled arrows, classical cytopathic effect in livers after viral infection—eosinophilic cytoplasm and intranuclear inclusion body; open arrow, lymphocytic infiltration; N, necrotic area. (G) Active caspase-3 levels (scoring as under Materials and Methods). Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (H) Representative examples of caspase-3 staining from each treatment group (original magnification 10 × 20). Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 5 Adenovirus gene expression, replication, and infection-induced pathologic changes in normal liver tissue in vivo are inhibited by E1B-19 kDa deletion. Viruses were injected intravenously as described to infect the livers of immunocompetent mice. Viral gene expression, replication, pathology, and apoptosis induction by each virus were compared. (A) E1A expression (early viral gene). Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (B) Representative examples of E1A staining from each treatment group (original magnification 10 × 20). (C) PFU (plaque-forming unit) recovery. Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (D) Cytopathic effect severity (scoring as under Materials and Methods). Open bars, 24 h postinjection; black bars, 48 h postinjection; gray bars, 120 h p.i. Error bars represent standard errors between different animals. *Undetectable. (E) Periportal inflammation severity (scoring as under Materials and Methods). Open bar, 24 h postinjection; filled bar, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (F) Representative examples of histopathology from each treatment group (original magnification 10 × 20). Filled arrows, classical cytopathic effect in livers after viral infection—eosinophilic cytoplasm and intranuclear inclusion body; open arrow, lymphocytic infiltration; N, necrotic area. (G) Active caspase-3 levels (scoring as under Materials and Methods). Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (H) Representative examples of caspase-3 staining from each treatment group (original magnification 10 × 20). Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 5 Adenovirus gene expression, replication, and infection-induced pathologic changes in normal liver tissue in vivo are inhibited by E1B-19 kDa deletion. Viruses were injected intravenously as described to infect the livers of immunocompetent mice. Viral gene expression, replication, pathology, and apoptosis induction by each virus were compared. (A) E1A expression (early viral gene). Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (B) Representative examples of E1A staining from each treatment group (original magnification 10 × 20). (C) PFU (plaque-forming unit) recovery. Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (D) Cytopathic effect severity (scoring as under Materials and Methods). Open bars, 24 h postinjection; black bars, 48 h postinjection; gray bars, 120 h p.i. Error bars represent standard errors between different animals. *Undetectable. (E) Periportal inflammation severity (scoring as under Materials and Methods). Open bar, 24 h postinjection; filled bar, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (F) Representative examples of histopathology from each treatment group (original magnification 10 × 20). Filled arrows, classical cytopathic effect in livers after viral infection—eosinophilic cytoplasm and intranuclear inclusion body; open arrow, lymphocytic infiltration; N, necrotic area. (G) Active caspase-3 levels (scoring as under Materials and Methods). Open bars, 24 h postinjection; filled bars, 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. (H) Representative examples of caspase-3 staining from each treatment group (original magnification 10 × 20). Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 6 Adenoviral gene expression and replication/persistence in replication-semipermissive murine tumor tissues in vivo. Viruses or PBS were injected on day 1 (109 particles) into JC tumors in immunocompetent mice. (A) E1A score (day 6 postinjection). Error bars represent standard errors between different animals. *Undetectable. (B) Plaque-forming unit (PFU) recovery data are shown on a per gram of tumor basis. Open bars, data from day 6; closed bars, day 10. Error bars represent standard errors between different animals. *Undetectable. Viruses (1 × 1010 particles) were injected on day 1 via tail vein into immunocompetent mice bearing CMT-167 tumors in the flank as described. (C) Hexon intensity score at various time points. Open bars, data from 24 h postinjection; filled bars, 48 h postinjection; gray bars, 120 h postinjection. Error bars represent standard errors between different animals. (D) PFU recovery data are shown on a per gram of tumor basis. Open bars, data from 24 h postinjection; filled bars, data from 48 h postinjection. Error bars represent standard errors between different animals. *Undetectable. Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions

Fig. 7 Antitumoral efficacy of E1B-19 kDa deletion mutant dl250 in vivo. PT45 human pancreatic cancer xenograft was implanted into C57BL/6 nu/nu mice as described. PBS or viruses (1 × 1010 particles) were injected intratumorally on days 1, 3, and 5. (A) Animal survival was monitored and compared. Both dl250 and Ad2wt treatment showed similar survival rates and both were higher than control group. (B) Tumor growth curve. Both dl250 and Ad2wt treatment groups showed significant delays in tumor growth compared with the PBS group. Molecular Therapy 2004 9, 786-803DOI: (10.1016/j.ymthe.2004.03.017) Copyright © 2004 The American Society of Gene Therapy Terms and Conditions